A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

This is a Phase IIb randomized, double-blind, placebo-controlled, multi-center, dose-ranging study to evaluate the efficacy, safety, and pharmacokinetic (PK) of AZD5462 on top of standard of care in 2 cohorts of participants with HF: Cohort A, and Cohort B. The study will include 3 periods and approximately 12 study visits: * Screening period of up to 4 weeks (at least 1 study visit) * Treatment period of 24 weeks (8 study visits) * Follow-up period of 4 weeks (3 study visits) Eligible participants in each cohort will be randomized equally 1:1:1:1 to receive a once daily dose (OD) of 3 dose levels (low, medium, or high) oral dose of AZD5462 tablets or placebo.